Mild cognitive impairment in Parkinson’s disease: the challenge and the promise by Fernandez, Hubert H et al.
Neuropsychiatric Disease and Treatment 2005:1(1) 37–50
© 2005 Dove Medical Press Limited. All rights reserved
37
REVIEW
Abstract: This review addresses the literature surrounding Parkinson’s disease (PD) and
mild cognitive impairment (MCI). It discusses the neuropsychological, pharmaceutical, and
pathological overlap, the socioeconomic impact of PD and MCI, and the value of recognizing,
understanding, and treating MCI in PD. It is concluded from this review that MCI in PD does
exist and should be considered in clinical and research investigations. Due to the lack of
accepted clinical criteria, an inclusive operating definition of MCI in PD is proposed. Research
guidelines for studying the presence of MCI in PD and evaluating the efficacy of pharmaceutical
interventions are also suggested.
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Introduction
Dementia in Parkinson’s disease (PD) and, in particular, mild cognitive impairment
(MCI) has been difficult to define. Dementia is generally considered an acquired and
persistent deterioration of the intellect in an alert person. What differentiates dementia
from other cognitive impairments, such as MCI, is that in dementia, cognitive
impairment results in a significant interference with work or usual social activities
(APA 2000). The latest DSM version defines dementia as “the development of multiple
cognitive deficits that include memory impairment and at least one of the following
cognitive disturbances: aphasia, apraxia, agnosia, or disturbance in executive
functioning. The cognitive deficits must be sufficiently severe to cause impairment
in occupational or social functioning and must represent a decline from a previously
higher level of functioning” (APA 2000, p 148). Dementia is, thus, largely a clinical
diagnosis corroborated by psychometric testing.
The 4 cognitive domains that can be affected include: (1) recent memory – the
ability to learn, retain, and retrieve newly acquired information; (2) language – the
ability to comprehend and express verbal information; (3) visual spatial function –
the ability to manipulate and synthesize non-verbal, geographic, or graphic
information; and (4) executive function – the ability to perform abstract reasoning,
solve problems, plan for future events, mentally manipulate more than one idea at a
time, maintain mental focus in the face of distraction, or shift mental effort easily.
This article discusses the different types of dementia, their socioeconomic impact
and how they relate to Parkinson’s disease (PD); provides an overview of MCI, its
definition and subtypes; describes the current challenges in understanding MCI in
PD; and discusses the value of recognizing, understanding, and treating MCI in PD.
Incidence and prevalence of dementia in
Parkinson’s disease
The definition and frequency of dementia in PD is controversial. Incidence rates for
PD dementia range from 4.2%–9.5% per year (Hughes et al 2000; Aarsland, Anderson,
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et al 2001). Depending on the sample population and criteria
used, the prevalence rate of PD dementia ranges from
10%–40%. If the higher prevalence rates are correct, PD
could be the second most common cause of dementia after
Alzheimer’s disease (AD).
One epidemiologic study estimates that 65%–70% of
demented individuals suffer from AD; 13%–15% have
dementia with Lewy bodies (DLB); 8%–10% have PD; and
5%–10% are due to vascular dementia. However, other
epidemiologic studies do not include PD as a major source
of dementia in the elderly (Meyer et al 1988; Pillon et al
1991; Wahlund et al 2003).
In a population-based study of PD with and without
dementia, the crude PD prevalence was 99.4/100 000 and
the crude PD dementia prevalence was 41.1/100 000. The
prevalence of dementia increased with age, from 0 (for < 50
years of age) to 787.1/100 000 (for > 79 years of age).
Interestingly, in that study, the major difference between
PD patients with and without dementia was a later onset of
motor manifestations in demented PD (Mayeux et al 1992).
By 2050, it is projected that the number of individuals
over 65 will increase to 1.1 billion worldwide. As a
consequence, the number of dementia cases may reach 37
million. By 2050, the total cost of dementia as an illness is
estimated to reach US$383 billion in the USA (Lockhart
and Lestage 2003).
More importantly, dementia seems to decrease survival
rates. The median survival of a person with dementia from
onset to death is about 6 years. A treatment capable of
delaying the onset of AD, for example, by 5 years (ie, 50%
risk reduction), reduces the prevalence rate of AD by 4.04
million by the year 2050. Delaying the onset by only
6 months reduces the number of demented patients by
380 000. From the medicoeconomic standpoint, this 6-month
delay in the onset of dementia is estimated to result in
average annual savings of US$18 billion by 2050.
Mild cognitive impairment
MCI is in an intermediate zone between normal cognition
and dementia. Clinicians view MCI differently. It is seen as
either a “disease” representative of a homogenous
population of individuals in an early prodromal stage of
clinically defined AD, or a heterogeneous “syndrome”
representing an early or transitional stage of different forms
of dementia. Through the years, various terms have been
used to describe the MCI state, such as, cognitively impaired
not demented, possible dementia syndrome, age-associated
memory impairment, and age-associated cognitive
impairment.
There are several subtypes of MCI that are believed to
represent prodromal stages for several dementing illnesses
(see Table 1). MCI can predominantly affect a single
cognitive memory (or non-memory) domain, or affect
multiple cognitive domains. The most well described and
studied of the MCI subtypes is the “amnestic” form. Its
working criteria are listed in Table 2. In amnestic MCI,
memory is affected to a significant degree (approximately
1.5 SD below age- and education-matched normal subjects),
while other domains might be very mildly impaired at
perhaps less than 0.5 SD below appropriate comparison
subjects (Petersen et al 1999). In multiple domain MCI,
several cognitive domains are impaired at perhaps the
0.5–1.0 SD level of impairment. Subjects may have slight
memory impairment in conjunction with mild impairment
in, eg, executive function and language. The distinction
between multiple domain MCI and amnestic MCI is that no
single domain is impaired out of proportion to the other
cognitive domains. Finally, a third clinical variety of MCI
could involve a mild impairment in a single non-memory
cognitive domain. This form of MCI, known as single non-
memory-domain MCI, is characterized by a person having
a relatively isolated impairment in a single non-memory
domain such as executive function, visuospatial processing,
or language.
Table 1 Heterogeneity of mild cognitive impairment in various
dementing states
Type of MCI May progress to:
Amnestic MCI Alzheimer’s disease
Multiple domains, mild impairment Alzheimer’s disease
Vascular dementia
Dementia with Lewy bodies
Normal aging
Single non-memory domain Frontotemporal demetia
Primary progressive aphasia
Dementia with Lewy bodies
Vascular dementia
Abbreviation: MCI, mild cognitive impairment.
Table 2 Amnestic mild cognitive impairment working criteria
1. Memory complaint, preferably corroborated by an informant
2. Objective memory impairment for age and education
3. Largely intact general cognitive function
4. Essentially preserved activities of daily living
5. Not dementedNeuropsychiatric Disease and Treatment 2005:1(1) 39
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Despite the guidelines listed above, the diagnosis of MCI
remains challenging. The standard deviation cut-offs used
for single domain (eg, –1.5 SD) or multiple domain (eg,
–0.5 to –1.0 SD) cannot be generalized to all patients. This
is because a patient’s premorbid level of functioning may
influence his/her performance on neuropsychological
measures (ie, measures of memory, attention, etc). For this
reason, researchers should also incorporate findings from a
clinical interview and a standardized assessment of
premorbid intellectual functioning (ie, traditional “hold”
domains of cognitive functioning) for diagnostic purposes.
These additional procedures are necessary when test norms
do not include correction scores for education level. Other
considerations for reducing diagnostic false positives include
using a more stringent cut-off score of –2.0 SD (where less
than 2% of the population score). Interestingly, however,
researchers tend not to use this stringent cut-off score out
of concern that they will fail to classify patients’ milder forms
of cognitive impairment. Consequently, despite literature
recommendations, there remains a fine balance between the
statistical and practical issues of use of cut-off scores for
MCI diagnostic purposes.
All subtypes of MCI are distinguishable from full
dementia. The cognitive impairment in MCI, although
objectively seen and subjectively noticed, is not severe
enough to sufficiently impair activities of daily living and
normal social functioning. Since MCI does not significantly
affect general day-to-day function, its definition should
therefore involve a combination of both clinical skill and
neuropsychological test findings.
The challenge
The incidence of dementia and MCI in
PD remains unclear
Due to the lack of a universal set of criteria to identify
cognitive impairment in PD, the reported prevalence of
dementia in PD ranges from 10%–95% (Marttila and Rinne
1976; Lieberman et al 1979; Boller et al 1980; Brown and
Marsden 1984; Mayeux et al 1988, 1992; Yoshimura 1988;
Friedman and Barcikowska 1994; Aarsland et al 1996).
One prospective study conducted over 3.5 years,
involving 140 non-demented PD and 572 controls, showed
19.2% of PD patients became demented within 2 years
compared with 15.2% of controls. Parkinson patients were
almost two times more likely to develop dementia compared
with controls (RR = 1.7; CI: 1.1–2.7). Predictive features
for dementia included a Unified Parkinson’s Disease Rating
Scale (UDPRS) score > 25 (ie, more severe motor impair-
ment) and the presence of depression (Marder et al 1995).
Even the rate of progression of the most well defined
MCI subtype (ie, amnestic MCI) to AD has not been
homogenous. The conversion rate ranges from 0% to 21%
at one year, 6%–33% between two and three years, and
37%–58% at five years. Remarkably, there are a relatively
high percentage of individuals who remain stable or revert
from MCI diagnosis back to normal. A 5-year prospective
study on MCI shows 39% converted to AD, 42 % remained
stable, and 19% showed improvement in their neuro-
psychiatric profiles, leading the authors to state that the
“large heterogeneity in the progression of suspected MCI
make it a difficult diagnostic entity … This suggests that
current psychometric criteria used to evaluate MCI are not
sufficiently refined …” (Petersen et al 1999, p 304).
However, despite the heterogeneity, longitudinal follow-
up studies show individuals with MCI consistently progress
to clinically probable AD at a rate between 6%–15% per
annum, and up to 70%–80% convert to full dementia within
10 years (Petersen et al 1999).
The etiology of dementia in PD is
heterogeneous
Most single photon emission computerized tomography
(SPECT) studies in PD show a heterogeneous regional
cerebral blood flow (rCBF) pattern. Three main subtypes
or patterns of hypoperfusion in PD with dementia are often
described. One study shows 22% of PD patients with
dementia exhibit frontal hypoperfusion, 64% have
temporoparietal hypoperfusion (similar to that seen in AD),
and 14% exhibit multiple focal deficits (similar to that seen
in vascular dementia) (Yoshimura 1988).
Another functional imaging study comparing the PET
scans of various dementing neurodegenerative illnesses
shows a clearer, more homogenous pattern for conditions
such as corticobasal ganglionic degeneration (CBGD) and
progressive supranuclear palsy (PSP) compared with PD,
DLB, or AD. CBGD patients uniformly exhibit asymmetric
hypometabolism of cortex and thalamus. PSP patients have
global reduction especially in the frontal lobe and basal
ganglia, whereas positron emission tomography (PET)
studies in AD, PD with dementia, and mild DLB all show a
similar resting pattern of frontotemporoparietal hypo-
metabolism. Ultimately this study led to the unsatisfactory
conclusion that “metabolic PET can distinguish CBGD andNeuropsychiatric Disease and Treatment 2005:1(1) 40
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PSP but not PDD, AD or DLB” (Turjanski and Brooks 1997,
p 37).
Although general rules are often followed, neuro-
psychological tests also show similar overlap, especially
between DLB and demented PD patients. As an example, a
study looking at the clinical and neuropsychological profiles
of 16 patients with DLB, 15 PD patients with dementia,
and 16 patients with AD found no difference in the
performance of various cognitive tasks such as verbal
memory, attention, visual perception, and construction.
Clinically, PD and DLB patients do not differ in the UPDRS
motor scores in this study (Noe et al 2004).
The pathology of these disorders does not aid in the
differentiation of cognitive impairment. One autopsy study
showed that up to 60% of clinically diagnosed PD patients
had senile plaques and neurofibrillary tangles in the
hippocampus or neocortex (Hakim and Mathieson 1978;
Duyckaerts et al 1993). Thus, it may be likely that only a
minority of demented PD patients have the classical
“subcortical” PD dementia. The rest of PD patients may
have superimposed AD-type dementia and/or dementia from
vascular causes (PD commonly occurs in the elderly, where
stroke risk factors are at their peak). Thus, the functional
imaging, neuropsychiatric profile, and pathology support
the heterogeneity of dementia in PD, and none of these
definitely differentiates the exact cause of cognitive
impairment. If the etiology of dementia in PD is, indeed,
heterogeneous and overlapping with other forms of
dementia, then its likely precursor, MCI in PD, is more likely
to be heterogeneous as well.
Further complicating this already confusing picture is
that DLB, a dementing illness strongly associated with
parkinsonian features, is still not recognized by all experts
as a separate disease entity from PD. There is increasing
consensus that DLB may be a variant of PD dementia, and
that both conditions may be the opposite ends of the
spectrum of one illness. The 3rd International Workshop on
DLB and PD dementia (Newcastle-upon-Tyne, UK; 2003
Sep 17–20) highlights the findings that the principal
correlate of dementia in PD is the presence of Lewy bodies
in the limbic and neocortex – similar to that of DLB. The
amount of concomitant AD pathology in PD dementia is,
however, typically less than that in classic DLB. The clinical
features of PD dementia are similar to those of DLB, with
attentional deficits, executive abnormalities, and frequent
concomitant neuropsychiatric disturbances, including visual
hallucinations and delusions. Participants from the 3rd
International Workshop on DLB and PD Dementia
supported abolishing the “1-year rule” that conveniently
separates PD dementia from DLB. Patients whose disease
begins with cognitive impairment will be diagnosed as
having DLB. Illnesses beginning with a parkinsonian
syndrome and meeting criteria for PD will be diagnosed
with PD dementia when dementia occurs, regardless of the
timing of its occurrence. This consensus, however, does not
solve the fundamental question of true etiology and the
significance of pathology to the clinical syndrome.
There is no uniform definition of MCI
especially in Parkinson’s disease
“How wide the net for MCI is cast will affect the prevalence
and severity of its functional consequences” (Albert et al
2002, p 64). A 5-year prospective study of 1790 geriatric
patients shows that the most commonly used case definition
of amnestic MCI yields a population prevalence estimate
of 1.03% (95% CI 0.66–1.40). Eliminating the requirements
for subjective memory complaints and intact activities of
daily living increases the prevalence to 3.02% (95% CI
2.4–3.64). However, the 5-year outcomes, including the risk
of death, institutionalization, and conversion to full
dementia, are not distinctly different among the various case
definitions of MCI. Regardless of the MCI criteria used,
most people with amnestic MCI develop dementia, chiefly
AD, after 5 years (RR = 9.3–19.7). Thus, in this large study,
variations in case definition affect prevalence but not
outcomes of MCI (Fisk et al 2003).
Although it may seem premature to propose an operating
criteria for MCI in PD, there are sufficient clinical,
psychometric, radiological, and pathological findings on
cognitive impairment in PD that help guide which principal
concepts should be incorporated in the future definition of
MCI. First, because MCI does not significantly affect
activities of daily living, it is dangerous to have purely
clinical MCI criteria. Its definition should be an equal
combination of clinical and psychometric criteria. Second,
the clinical criteria for “probable” idiopathic PD need to be
strictly incorporated. Third, because of the heterogeneity
of dementia in PD, the three main subtypes of MCI
(amnestic, multiple domain, single-non-memory domain
type), which could all lead to dementia in PD, should be
included in the clinical and psychometric criteria.
Due to the lack of accepted criteria for MCI in PD, an
inclusive operating definition is proposed below:
1. Meet the clinical criteria for “probable” idiopathic PD
(eg, having at least 2 out of 3 features of parkinsonism:Neuropsychiatric Disease and Treatment 2005:1(1) 41
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resting tremor, bradykinesia, rigidity; with a sustained
significant response to dopaminergic therapy).
2. Clinically:
a. Memory complaint (forgetfulness) OR complaints
in attention/executive function (slowed thinking,
difficulty manipulating information, lack of
concentration, etc) OR isolated complaints on other
domains such as visuospatial processing or language;
preferably corroborated by an informant.
b. Essentially preserved activities of daily living.
c. Not demented.
3. Psychometrically:
a. Largely intact general cognitive function.
b. With an objective impairment (that corresponds to
the above subjective complaints) as measured
psychometrically: ie, 1.0–1.5 SD below age- and
education-matched normal subjects in one cognitive
domain, such as memory or other single non-memory
domain, while other domains are mildly affected at
less than 0.5 SD below appropriate controls; OR
0.5–1.0 SD level of impairment in several cognitive
domains.
4. Absence of delirium or other organic causes of cognitive
impairment.
It is unlikely that a “perfect” criterion for MCI in PD will
ever be proposed to the satisfaction of all experts in the field.
The ranges of cognitive performance are only descriptive
guidelines and do not imply specific cutoff scores. There
will probably be a need, at some point, to specifically define
what cognitive decline is from premorbid level of ability,
factoring for “normal age-related decline” and that which
is viewed as “acceptable decline” in PD.
The risk and rate of cognitive decline in
PD can be variable depending on the
population subset
Identified risk factors for dementia in PD include older age,
later PD onset, male gender, longer durations of symptoms,
specific aspects of cognitive dysfunction (eg, decreased
verbal fluency), predominance of axial motor symptoms,
and the presence of MCI (Marttila and Rinne 1976; Elizan
et al 1986; Jacobs et al 1995; Mahieux et al 1998; Aarsland,
Anderson, et al 2001; Levy, Jacobs, et al 2002; Levy, Schupf,
et al 2002).
In a prospective cohort study, 250 non-demented patients
with PD were evaluated for incident dementia after 5 years.
Seventy-four of the patients became demented after 5 years.
Odds ratios (OR) for incident dementia with PD were
increased for the following: being older than 70 years of
age (2.7; 1.4–5.5), having a UPDRS motor subscale score
of greater than 25 (3.0; 1.5–6.2), being depressed (2.7;
1.5–6.6), being confused or psychotic on levodopa (3.3;
1.3–8.7), and interestingly, having facial masking as a
presenting sign (6.1; 1.4–26.9) (Stern et al 1993).
Predicting and identifying the subset of a population that
would most likely convert to dementia could be misleading.
One study followed 647 geriatric subjects over 3 years to
identify if “preclinical syndromes” for AD, vascular
dementia, and PD-related dementias existed. Each subject
was asked to participate in a medical assessment that
included a standardized medical history, neuropsychological
protocol, and physical examination. Preclinical syndromes
for the three predominant dementias (AD, vascular dementia,
and PD dementia) and their combinations were defined using
cognitive, motor, and vascular features. In this study,
preclinical syndromes were defined as having cognitive
impairment displaying mild to moderate deficits in one or
more areas of cognition but not meeting DSM-IIIR criteria
for dementia; vascular features based on arteriopathy score
(weighted points for the presence of atrial fibrillation,
diabetes, hypertension, heart disease, claudication,
hypercholesterolemia, and smoking history) and a vascular
score (weighted points for the presence of cerebrovascular
disease such as stroke and transient ischemic attacks); and
extrapyramidal features based on an extrapyramidal score
(rigidity, cogwheeling, slowed fine finger movements) and
the presence of an extrapyramidal gait disorder. Preclinical
syndromes affected 55.7% (299/647) and showed increased
odds of developing dementia (OR: 4.81; p < 0.001).
Although the presence of preclinical syndromes were highly
sensitive at detecting 52 of 58 (89.7%) incident dementias,
268 (80.6%) of the subjects with preclinical syndromes did
not show dementia over 3 years (positive predictive value
of 19%). Subjects defined as having a combination of
cognitive, extrapyramidal, and vascular features were at
greatest risk of progressing to dementia (Waite et al 2001).
Can medications possibly influence
performance on cognitive tests?
Common PD medications appear to influence performance
on cognitive measures. Both impairments and improvements
have been reported. For example, in an open-label
randomized study of 28 right-handed patients with
early/mild PD who obtained baseline and repeatNeuropsychiatric Disease and Treatment 2005:1(1) 42
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neuropsychological and clinical assessments during 3
treatment conditions: a baseline “off” treatment condition;
an “on” with pramipexole (a dopamine agonist) condition;
and an “on” with levodopa condition. In comparison to the
baseline (“off” condition), when medicated with
pramipexole, patients showed a significant impairment in
short-term memory, attentional-executive functions, and
verbal fluency. In contrast, these impairments were not
observed with the “on” levodopa condition relative to
baseline. Although not exceeding normative values, this
study showed that various PD medications may influence
cognitive functions or cognitive testing ability (Brusa et al
2003). Moreover, a decline in cognitive abilities has also
been reported when there is medication withdrawal.
Specifically, it has been reported that levodopa withdrawal
in PD selectively impaired cognitive performance tests
sensitive to frontal lobe dysfunction (Lange et al 1992).
Positive changes or improvements in cognitive
functioning have been reported with other medications. For
example, pergolide (another dopamine agonist) (Perachon
et al 1999) and levodopa (Lange et al 1995) are reported to
improve tests sensitive to frontal lobe dysfunction in PD
patients. The difference in the cognitive effects between the
2 dopamine agonists (pramipexole and pergolide) is
attributed to the sedative effect of pramipexole and the D1
receptor affinity of pergolide.
These findings speak to the importance of considering
medications during the evaluation for cognitive changes in
PD. When differences in cognitive decline are subtle, like
that in PD patients with MCI, appreciating cognitive changes
that may be due to medications is essential. Appropriately
timing neuropsychological testing to on and off medication
periods needs to be recorded for appropriate cognitive
monitoring and MCI diagnosis.
The promise
The pathology in PD and AD, for which
cholinesterase inhibitors are principally
used, is similar
Cholinergic networks mediate aspects of memory and
attention in animal and human studies, and are similarly
damaged in PD and AD (Tiraboschi et al 2000). In autopsy
series, striking cell loss is found in the nucleus basalis of
Meynert. Additionally, choline acetyltransferase (ChAT)
activity has consistently been reported to be decreased to
approximately 40%–60% of control values in frontal,
temporal, and hippocampal cortex. These changes were
accompanied by a decrease in acetylcholinesterase (AChE)
activity (Ruberg et al 1982; Perry et al 1991, 1993; Mattila
et al 2001). In cases of PD with dementia, ChAT activity
has been shown to be low in the neocortex compared with
the hippocampus (Kuhl et al 1996). Cognitive impairment
in these cases seemed to correlate significantly with both
prefrontal ChAT activity (r = –0.52, p = 0.005) and the
density of D1 dopamine receptors in the caudate nucleus
(r = –0.40, p = 0.037) (Mattila et al 2001).
Nicotinic cholinergic receptor binding in the putamen
is also decreased in PD (Martin-Ruiz et al 2002). However,
muscarinic cholinergic receptors have been reported to be
relatively spared in PD with dementia when compared with
AD (Perry et al 1991). Therefore, from a theoretical point
of view, there may be a strong rationale for testing
cholinesterase inhibitors in individuals with PD (Aarsland
et al 2002).
Cholinesterase inhibitors ‘work’ in
cortical, subcortical, and mixed forms of
dementia
Four members of this class of compounds are currently
FDA-approved for the treatment of mild to moderate AD.
Tacrine, donepezil, rivastigmine, and galantamine are all
inhibitors of AChE enzyme and, in theory, help repair brain
cholinergic deficits by increasing the amount of
acetylcholine available for binding to cholinergic receptors
in the synaptic cleft.
The pharmacokinetic properties and in vivo ability to
modulate cholinergic networks of each of these compounds
are somewhat different. Tacrine and rivastigmine inhibit a
second enzyme, butryl cholinesterase, whose activity seems
to be up-regulated in AD and may parallel senile plaque
formation. Galantamine has additional properties as an
allosteric modulator of presynaptic nicotinic cholinergic
receptors.
Each of these compounds show comparable efficacy in
maintaining the Alzheimer’s disease Assessment Scale-
cognitive portion (ADAS-cog) scores above baseline in
double-blind controlled studies (Rogers and Friedhoff 1998;
Rogers, Doody, et al 1998; Rogers, Farlow, et al 1998; Rosler
et al 1999; Farlow et al 2000; Raskind et al 2000; Tariot et
al 2000; Corey-Bloom 2003). Also, brain metabolism by
fluorodeoxyglucose-positron emission tomography (FDG-
PET) has been shown to increase in tandem with clinical
benefit (Potkin et al 2001). In observational studies, long-
term use of cholinesterase inhibitors translates into a 2-yearNeuropsychiatric Disease and Treatment 2005:1(1) 43
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delay in admission to nursing homes (Winblad et al 2001;
Lopez et al 2002). In a landmark long-term 5 mg–10 mg
donepezil vs placebo randomized study by the AD2000
Collaborative Group (AD2000 2004), however, there was
no significant reduction in symptom progression or
institutionalization among AD patients. Clearly, additional
long-term randomized studies investigating the benefits of
pharmaceutical agents on disease progression are needed.
Interestingly, there have been increasing reports of
benefit using AChE inhibitors for dementias that involve
subcortical disease processes.
Erkinjuntti et al (2002) investigated the effects of
galantamine on 592 patients with vascular or mixed (AD
with cerebrovascular disease) dementia using the
Alzheimer’s disease assessment cognitive subscale (ADAS-
cog) and the clinician’s interview-based impression of
change plus caregiver input (CIBIC-plus) as primary
endpoints. In this study, galantamine showed greater efficacy
than placebo on ADAS-cog (galantamine change –1.7 vs
placebo +1.0; treatment effect 2.7 points; p < 0.0001) and
CIBIC-plus (74% vs 59% remained stable or improved;
p = 0.001).
Similary, there are several reports of rivastigmine and
donepezil use in vascular and mixed dementia with
comparable positive results (Kumar et al 2000; Moretti et
al 2001, 2004).
Closer to PD pathology, positive effects of AChE have
been reported in DLB. In a 23-week, prospective,
randomized double-blind, placebo-controlled, multicenter
study, 120 patients with DLB were given up to 12 mg of
rivastigmine daily or placebo for 20 weeks followed by 3
weeks rest (McKeith et al 2000). Patients treated with
rivastigmine showed statistically significant improvement
in cognition as measured by the Cognitive Drug Research
(CDR). Overall Speed score at week 12 (p < 0.01) and week
20 (p < 0.05). Rivastigmine showed a mean improvement
of 1.5 points in the Mini-Mental State Examination
(MMSE), while the placebo patients declined by a mean of
0.1 point at week 20 (p = 0.072). Moreover, patients taking
rivastigmine were significantly less apathetic and anxious,
and had fewer delusions and hallucinations while on
treatment than controls. These significant improvements in
behavior were measured by the scores on the 4-item
Neuropsychiatric Inventory (NPI) (p < 0.05) and the 10-item
NPI (p < 0.01).
Finally, the reported use of cholinesterase inhibitors
among the cognitively-impaired PD population is slowly
gaining momentum. The use of the first cholinesterase
inhibitor, tacrine, in the AD population was accompanied
by anecdotal evidence of worsened parkinsonism (184):
reports of fulminant hepatotoxicity resulted in the addition
of a warning label. Only a very modest clinical benefit was
initially appreciated by clinicians using tacrine. Because of
problems with tacrine, enthusiasm for larger trials of this
class of compounds in PD was reduced. Nonetheless, a small
open-label trial of this compound (n = 7) in PD patients with
psychosis reported 5 patients with complete resolution and
2 patients with partial improvement of hallucinations. The
mean MMSE score improved by 7.1 points and the UPDRS
motor scores improved dramatically (Hutchinson and
Fazzini 1996).
It was not until recently that investigators began to
reconsider the potential of these compounds for treating
dementia in PD (Geizer and Ancill 1998; Kaufer et al 1998;
Shea et al 1998; Aarsland et al 1999; Lanctot and Herrmann
2000; McKeith et al 2000; Samuel et al 2000; Skjerve and
Nygaard 2000; Grace et al 2001; Maclean et al 2001; Rojas-
Fernandez 2001). This change was encouraged by slow
confirmation of the more benign side-effect profiles of the
remaining three cholinesterase inhibitors and reports of
better efficacy in treating the cognitive and neuropsychiatric
concomitants of DLB.
Another report, also an open-label study, consisted of
eleven patients (average age 75 years) with PD dementia,
who were treated for 26 weeks with either tacrine (7 patients)
or donepezil (4 patients). For the combined group, scores
for the ADAS-cog improved by 3.2 points (p < 0.012). No
change in motor function as assessed by the Short Parkinson
Evaluation Scale (SPES) was noted (Werber and Rabey
2001). Behavioral symptoms were not mentioned.
In an open-label trial of 12 PD patients with drug-
induced psychosis (Reading et al 2001), rivastigmine was
initiated at 1.5 mg bid (twice a day) and increased every 2
weeks until either the maximum of 6 mg bid or the highest
tolerated dose was achieved. The drug was well tolerated.
Three withdrew, one due to death from unrelated sepsis,
one because the caretaker became ill, and the third from
nausea. The MMSE improved from 20.8 to 25.4 while the
UPDRS motor scale did not change. The mean NPI score
improved on the subscales measuring hallucinations and
sleep disturbances. Caregiver distress also improved. Repeat
measurements after a 3-week withdrawal showed a
comparable decline. No worsening of tremor or
parkinsonism was noted.
Another open-label pilot study with rivastigmine has not
yet been published in a peer-reviewed forum (KorczynNeuropsychiatric Disease and Treatment 2005:1(1) 44
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2002). Nineteen patients “with severe PD associated
dementia” were evaluated at baseline, after 26 weeks of
treatment and following an 8-week washout period. The
average dose from weeks 12 though 26 of treatment was
approximately 7.5 mg/day. Significant changes in total
ADAS-cog and the attention subscore of the MMSE (both
p < 0.004) were reported, but the actual scores were not
given. The comment was made that “enhancement of tremor
was the only extrapyramidal symptom that worsened in some
patients”.
The results of the first randomized, double blind,
placebo-controlled, crossover study were reported in 2002
(Aarsland et al 2002, 2003). Fourteen individuals with PD
and cognitive impairment were assigned to either donepezil
(5 or 10 mg/d) or placebo during two sequential periods
lasting 10 weeks each. Patient characteristics at baseline
included: a history of cognitive decline beginning one year
or more after the onset of parkinsonism (3.0 ± 2.6 years);
average duration of PD 10.8 ± 5.2 years; mean age 71.0 ± 3.9
years; and average levodopa dose 485 ± 256 mg/d. The
average MMSE score at study entry was 20.8 ± 3.4, with all
patients showing evidence of decline in memory and at least
one other category of cognitive function. Significant effects
of donepezil compared with placebo for MMSE (2.1 ± 2.7
vs 0.3 ± 3.2, p = 0.013) and the CIBIC (3.3 ± 0.9 vs
4.1 ± 0.85) were noted. Motor UPDRS subscores did not
worsen during donepezil treatment. Three patients had
improved scores on delusions, 2 on hallucinations, 1 on
agitation, 6 on depression, and 5 on apathy. None of these
improvements were statistically significant due to the low
scores on these items at baseline and the small number of
subjects involved.
The same group of authors reported their findings on 16
PD patients with dementia who were treated open-label with
galantamine (Aarsland et al 2003). Improvement in global
mental symptoms was noted in 8 patients, whereas
worsening was noted in 4. Hallucinations improved in 7 of
the 9 patients (all with hallucinations before treatment).
Parkinsonism improved in 6, but a mild worsening of tremor
was noted in three. Clock drawing improved (p = 0.0016)
(Agid et al 1986; Aarsland, Bronnick, et al 2001, 2003).
In addition, two small case series targeting individuals
with PD and dementia with psychosis had recently been
added to the literature. The first involved 6 individuals
treated with donepezil up to 10 mg/day for 6 weeks of
treatment, without obvious deterioration of parkinsonian
symptoms (Bergman and Lerner 2002); the second, used
rivastigmine (Bullock and Cameron 2002). Neither study
noted obvious deterioration of parkinsonian symptoms or
paradoxical worsening of behavior.
MCI can be identified and successfully
followed
As an example, one multicenter study followed 769 patients
with MCI: 107 cognitively normal elderly controls, and 122
patients with very mild AD (Clinical Dementia Rating,
CDR = 0.5); 183 patients with mild AD (CDR = 1.0) to
determine whether vitamin E or donepezil was effective at
delaying the time to a clinical diagnosis of AD (Grundman
et al 2004). ADAS-cog scores were 5.6 +/–3.3 for controls,
11.3 +/–4.4 for patients with MCI, 18.0 +/–6.2 for AD CDR
group 0.5, and 25.2 +/–8.8 for the AD CDR group 1.0.
Moreover, patients with MCI had hippocampal volumes that
were intermediate between those of controls and patients
with AD. The authors concluded that patients with MCI were
intermediate between clinically normal individuals and
patients with AD on cognitive, functional, and radiological
ratings. It demonstrated the successful implementation of
operational criteria for this group of at-risk patients in a
multicenter clinical trial.
Table 3 outlines the agents currently being tested in MCI
states. Computerized cognitive assessment systems are now
being used for its ease and low cost in longitudinal testing,
especially in MCI states. Validation studies are able to
classify individuals as cognitively healthy, MCI, or mild
AD on the basis of computerized cognitive tests (Doniger
et al 2003).
The state of MCI in various types of dementia has
recently been investigated more carefully. The Mayo Clinic
Registry identified 21 patients with clinically probable DLB
who had been previously characterized as having MCI.
Similar to that predicted in PD, the previous MCI states
prior to DLB were heterogeneous. Ten patients had the
amnestic form of MCI, 6 had single non-memory domain
Table 3 Agents currently being tested in mild cognitive
impairment states
Agent Outcome measurement Study duration
Donepezil Change in cognitive function 6 months
Donepezil Conversion to AD 36 months
Galantamine Conversion to AD 24–36 months
Rivastigmine Conversion to AD 24–36 months
Rofecoxib Conversion to dementia 24–36 months
Vitamin E Conversion to AD 36  months
CX-516 Change in cognitive function 1 month
Piracetam Change in cognitive function 12 months
Abbreviation: AD, Alzheimer’s disease.Neuropsychiatric Disease and Treatment 2005:1(1) 45
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MCI, 4 had multiple domain MCI with amnesia, and 1 with
multiple domain MCI without amnesia. The authors then
concluded that unlike AD, where the majority of patients
evolved from an amnestic form of MCI, each of the MCI
subtypes could convert into DLB.
MCI states even among elderly patients with vascular
risk factors are also becoming recognized (Geroldi et al
2003).
Biomarkers may help in identification
and longitudinal follow-up of MCI
patients
In AD, it has been recognized that as cognitive impairment
worsens from normal to MCI to full-scale dementia,
hippocampal volume inversely decreases (Xu et al 2000).
One study classified 80 patients with MCI into 3 groups
according to their hippocampal volume: > 50th percentile,
< 50th percentile, and < 1st percentile compared with normal
controls. During the period of longitudinal observation,
which averaged 32.6 months, 27 of the 80 MCI patients
became demented. Hippocampal atrophy at baseline was
significantly associated with crossover from MCI to AD
(relative risk 0.69, p = 0.015). Moreover, the risk for
conversion to full dementia in the next 5 years followed 3
separate curves, the steepest coming from the group with
hippocampal volumes < 1st
 percentile from the normal
controls (Jack et al 1999).
This anatomical marker had also been described in PD
and parkinsonism (Camicioli et al 2003). One study
compared the hippocampal volumes between 10 PD, 10 PD
patients with MCI or dementia, 11 AD, and 12 controls.
The “effect sizes” compared with the control group were:
0.66 for the PD group, 1.22 for the PD group with cognitive
impairment, and 1.81 for the AD group. The authors
concluded that progressive hippocampal volume loss in PD
paralleled cognitive impairment. They felt these findings
could be quantitated and could provide an early marker for
dementia in PD (Camicioli et al 2003).
Rates of cerebral atrophy have been correlated with
measures of cognitive decline in PD. Serial volumetric T-1
weighted MRI on 8 non-demented PD vs 10 age-matched
controls was performed. PD patients had reduced annual
brain volume loss compared with controls (p < 0.001). Also,
a significant correlation was seen between reduction in brain
volume and reduction in performance IQ (r = 0.84; p = 0.004)
and full scale IQ (r = 0.63; p = 0.049) (Hu, White, Chaudhuri,
et al 2001; Hu, White, Herlihy, et al 2001).
Some cognitive tests can be sensitive
enough to detect cognitive impairment
even in early PD
Many studies have now established that patients with PD
develop mild neuropsychological deficits across a range of
cognitive functions (Lees and Smith 1983; Boller et al 1984;
Weingartner et al 1984; Taylor et al 1986, 1987; Sagar,
Cohen, et al 1988; Sagar, Sullivan, et al 1988; Pillon et al
1996). However, not all neuropsychological tests are equally
sensitive in detecting MCI in PD or in following progression
Table 4 Cognitive tests reported to be sensitive in detecting subtle changes in Parkinson’s disease
Cognitive domain Test Author
Visuoperception impairment Visuoconstructional ability, eg, Rey-Osterrieth Complex Figure  Freeman et al 2000
Visuospatial, eg, Raven’s Progressive Matrices  Farina et al 2000
Face recognition memory  Levin et al 1989; Levin 1990;
Haeske-Dewick 1996; Cousins et al 2000
Spatial memory  Levin 1990; Pillon et al 1996;
Giraudo et al 1997; Pillon et al 1997;
Postle, Jonides, et al 1997;
Postle, Locascio, et al 1997
Learning and memory deficits Procedural learning  Vakil and Herishanu-Naaman 1998;
Koenig et al 1999
Incidental (not intentional) new learning of verbal material  Ivory et al 1999
Delayed recognition memory  Stebbins et al 1999
Explicit memory  Appollonio et al 1994 
Free recall  Breen 1993 
Attentional deficits Disinhibition of automatic word reading Henik et al 1993
Attentional set-shifting ability  Owen et al 1992 
General cognitive test Weschler Adult Intelligence Scale–Revised as a Peavy et al 2001
Neuropsychological Instrument (WAIS-RNI)Neuropsychiatric Disease and Treatment 2005:1(1) 46
Fernandez et al
of cognitive impairment in PD (Jacobs et al 1995). Table 4
lists the neuropsychological tests reported to be sensitive in
detecting subtle cognitive changes in PD. Some cognitive
tests are consistently unimpaired in early PD such as Digit
Span, Information, and Boston Naming Test; while some
neuropsychological tests show mixed reports, such as
Logical Memory, Associate Learning, Word Fluency Test
(Levin et al 1989; Cooper et al 1991; McFadden et al 1996;
Ross et al 1996; Kuzis et al 1997, 1999).
At the University of Florida Movement Disorders Center,
a retrospective analysis comparing the neuropsychological
profile of random PD patients to their “on” UPDRS-Motor
scores was performed. The complete neuropsychological
profile performed in the “on” state included the MMSE,
Dementia Rating Scale (DRS); and tests for general
intelligence (WAIS 3, Vocabulary subtest); attention and
concentration (Digit Span); Verbal Memory (HVLT,
WRAT); language (Boston Naming, Controlled Oral Word
Association Test); visual-spatial (Judgment of Line
Orientation, Facial Recognition Test); and executive function
(Stroop, Trail Making Test). The cognitive profiles of 60
PD patients (43 males and 17 females), with a mean age of
68 years (range: 51–88), and an average of 15 years of
education (range: 9–21) were analyzed. MMSE (r = –0.73;
p < 0.001), DRS (r = –0.45; p < 0.001), and most test scores
in all cognitive domains were inversely correlated to the
UPDRS motor scores. In addition, a significant association
was found between the UPDRS motor scores and MMSE
(r2 = 0.480; F (1, 51) = 47.08; p < 0.001) or DRS (r2 = 0.205;
F(1, 51) = 13.1; p < 0.001), independent of age and level of
education. In this cohort, cognitive impairment paralleled
motor deterioration (Fernandez et al 2003).
Cholinesterase inhibitors may delay
cognitive decline even among demented
patients
There are at least 2 long-term, multicenter studies that
suggested the early use of AChE inhibitors could offer
sustained and greater benefits compared with delayed
treatment. In one study, 158 patients with AD who originally
participated in a double-blind, placebo-controlled
multicenter trial using rivastigmine, agreed to continue on
the open-label phase (Doraiswamy et al 2002). The
rivastigmine groups (originally randomized to 1–4 or
6–12 mg/day) experienced significantly smaller declines in
ADAS-cog scores from baseline than the projected placebo
group after 52 weeks. Patients receiving rivastigmine
experienced significantly less decline compared with
patients originally receiving placebo and then initiating
rivastigmine treatment after a 6-month delay.
Similarly, in the 6-month, double-blind, multicenter
study using galantamine in AD followed by a 6-month open-
label phase, subjects who were initially randomized to
placebo never caught up in their ADAS-cog scores at the
end of the 6-month open-label phase compared with the
subjects who were initially randomized to galantamine
(Raskind et al 2000).
The solution
Two traditional schools of research, divergent yet com-
plementary, contribute to scientific advancement: the ‘micro-
scopic’ and the ‘macroscopic’ approach. Understanding MCI
through the microscopic approach often uses smaller-scale,
hypothesis-driven studies on a subset of cognitively-
impaired PD patients or a specific aspect (eg, pathology,
genetics, functional anatomy) of MCI. This approach seeks
to understand the basic defect(s) in MCI and tries to
determine what triggers the cascade of progressive,
irreversible cognitive decline, obtaining small pieces of
information until the entire puzzle is solved. From the
present review of literature, it is clear that there is a need to
develop more accurate biomarkers or predictors of cognitive
impairment; a better identification and delineation of the
roles of various neurotransmitters; a clearer understanding
of basal ganglia circuitry and how it contributes to dementia
in PD; and a system of sorting out the overlapping pathology
of dementia subtypes. More autopsy reports from patients
with MCI are needed. Negative reports and anecdotal cases
are required to help to fill an important vacuum of
knowledge. The macroscopic approach is favored by a
clinical trialist who seeks to understand a process from a
more panoramic perspective. It attempts to learn how MCI
progresses, and which sub-population progresses slower or
faster, and how evolution to full dementia can, thus, be
prevented. Although it may still be premature, the present
literature, can similarly guide us in developing a well
designed, placebo-controlled, parallel-group, multicenter
trial on MCI in PD. Given the information we have to date,
the “ideal” multicenter study testing an agent’s potential in
slowing disease progression should have the following
characteristics:
1. The inclusion criteria of MCI in PD should be strict but
must encompass all subtypes of MCI. Given the
pathologic and radiologic heterogeneity of dementia in
PD, the MCI subtypes that eventually progress to
dementia, just like that of DLB, is also probablyNeuropsychiatric Disease and Treatment 2005:1(1) 47
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heterogeneous. Thus, a multicenter or longitudinal trial
that confines its inclusion criteria to only specific
subtypes of MCI are mostly likely unable to represent
the true picture of cognitive decline in PD.
2. The study should be large enough. Because the rate of
progression and the degree of treatment response of each
MCI subtype that leads to PD dementia is unclear, the
ideal study requires a large sample.
3. The study duration should be long enough to see a
“separation”. Since the cognitive decline is progressive
and the success of a treatment is measured by a slower
decline or the delay (or prevention) of certain
neurobehavioral features (eg, psychosis) rather than
improvement in cognition, the study should be of
sufficient duration to see a divergence of treatment
groups over time. Results of studies involving smaller
samples and/or shorter periods of observation are more
likely to lead to a false statistical interpretation.
4. The inclusion criteria for idiopathic PD should be
stringent. Careless addition of cases of essential tremor,
multiple systems atrophy, progressive supranuclear
palsy, and DLB will make interpretation challenging,
especially when cognitive changes from year to year are
too subtle to clinically or even statistically appreciate.
5. Choose the specific tests wisely in the
neuropsychological protocol. Not all neuropsychological
tests are equal in sensitivity in detecting subtle cognitive
impairment, especially in PD. Some cognitive domains
are more affected than others in PD, and only certain
neuropsychological tests within that cognitive domain
are able to measure minimal cognitive changes.
6. Consider using a biomarker. Not all biomarkers are
equal. Functional biomarkers, such as SPECT and PET
scans, may be difficult to use because of the
heterogeneity in the blood flow patterns of PD patients
with dementia or MCI. Anatomical markers such as
hippocampal volume measurement seem to be more
consistent. Better biomarkers are needed.
7. The timing of neuropsychological tests should be uniform
in relation to drug intake. Most common drugs such as
pramipexole and levodopa can have opposite effects in
neuropsychological test performance. Similarly, the “on”
and “off” state of a PD patient can equally influence
performance. When differences are subtle and are
appreciated only when measured over time, controlling
for environmental factors is essential.
8. Consider outcome measures that will speak to the
pragmatic use of drugs. The recent large-scale
randomized study on donepezil vs placebo completed
by the UK AD2000 Collaborative Group (AD2000,
2004) demonstrates the importance of including
appropriate pragmatic outcome measures for clinical trial
research. Such outcome measures include changes in
comorbidity status, caregiver level of burden, psychiatric
and behavioral symptoms, institutionalization, and
formal care costs.
In summary, the best chance of halting a progressive illness
like cognitive decline/MCI in PD will be through discovery
and experimentation at the earliest possible time, and will
be accomplished by simultaneously employing both micro-
and macroscopic approaches.
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